Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims show mixed alignment with the FDA-approved label. Four dosing-related claims are supported by the label, several are not supported or only partially supported, and a number of statements are not supported by the label at all. No explicit contradictions were identified in the provided claim evaluations.
Category Scores
Accurate Statements
240 mg every 2 weeks is equivalent to ~3 mg/kg for an 80-kg patient.
2.2; 12.3
480 mg every 4 weeks is equivalent to ~3 mg/kg for an 160-kg patient.
2.2; 12.3
Some protocols (e.g., melanoma) allow the flat 240 mg every 2 weeks.
2.2
Others (e.g., NSCLC) may prefer 480 mg every 4 weeks for convenience.
2.2
Unsupported Statements
The standard nivolumab regimen is 3 mg/kg of body weight given intravenously every two weeks.
Label lists multiple dosing regimens (including weight-based and flat-dose options); does not designate 3 mg/kg as the sole standard.
3 mg/kg was the dose first shown to be effective in early clinical trials.
Label does not provide historical efficacy origins.
3 mg/kg ensures similar drug exposure across a wide range of body weights.
Label PK data do not state this generalization.
FDA and EMA approvals for many cancers use this weight-based schedule.
Label does not summarize regulatory approvals by agency or cancer in this manner.
For very low-weight patients (<30 kg), a flat dose may still be used.
Pediatric dosing exists but the label does not explicitly state a universal flat-dose approach for very low-weight patients.
The 3 mg/kg figure is generally retained.
Label shows multiple dosing options; does not imply the 3 mg/kg figure is the sole or primary retained approach.
No major safety differences have been observed between weight-based and flat dosing; the choice is mainly logistical.
Label does not provide a comparative safety conclusion between dosing strategies.
The most common 'per-kg' dose of nivolumab in adults is 3 mg/kg IV every two weeks.
Label lists multiple regimens; does not define a single most common per-kg dose.
Clinicians often switch to a flat dose (240 mg or 480 mg) to simplify scheduling.
Label acknowledges multiple regimens but does not discuss the frequency of switching in practice.
Pharmacologic exposure is essentially the same between weight-based and flat dosing.
Label discusses PK but does not explicitly claim equivalence of exposure across dosing strategies.
Contradictions
Important Omissions
Indications and usage details beyond dosing; the label provides numerous indications per table but the claims do not address these indications explicitly.
Importance:
High
Administration instructions (e.g., 30-minute IV infusion duration) and administration notes.
Importance:
High
Contraindications and boxed warnings (safety-related language) and monitoring considerations.
Importance:
High
Monitoring recommendations and adverse event management across dosing regimens.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation is based on alignment of dosing claims with label; no new safety claims are introduced by the claims evaluated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims about dosing history and exposure generalizations are not supported by the label; only a subset of dosing statements align with approved label options.
Suggested Improvement
Limit claims to label-supported dosing regimens (e.g., 240 mg every 2 weeks, 480 mg every 4 weeks, 3 mg/kg every 2 weeks for specific pediatric weights) and provide explicit label citations for each dosing assertion; avoid asserting historical efficacy or broad pharmacokinetic generalizations unless explicitly stated in the label.